News
IPHA
1.808
+2.02%
0.036
Weekly Report: what happened at IPHA last week (0720-0724)?
Weekly Report · 1d ago
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
Barchart · 5d ago
Innate Pharma completes enrollment in dose escalation of IPH4502 study
TipRanks · 07/21 09:30
Innate Pharma Completes Phase 1 Enrollment Of Nectin-4 Exatecan ADC IPH4502, Guiding Dose Optimization With Year-End Preliminary Data Readout
Benzinga · 07/21 05:28
Innate Pharma completes Phase 1 dose-escalation enrollment for Nectin-4 ADC IPH4502 study
PUBT · 07/21 05:06
Innate Pharma notifies availability of press release on IPH4502 Phase 1 dose-escalation enrollment completion
PUBT · 07/21 05:00
Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
Barchart · 07/21 00:00
Weekly Report: what happened at IPHA last week (0713-0717)?
Weekly Report · 07/20 09:09
Weekly Report: what happened at IPHA last week (0706-0710)?
Weekly Report · 07/13 09:09
Analysts Offer Insights on Healthcare Companies: Innate Pharma (IPHA), BrightSpring Health Services, Inc. (BTSG) and Spyre Therapeutics (SYRE)
TipRanks · 07/06 10:10
Weekly Report: what happened at IPHA last week (0629-0703)?
Weekly Report · 07/06 09:10
Weekly Report: what happened at IPHA last week (0622-0626)?
Weekly Report · 06/29 09:09
Weekly Report: what happened at IPHA last week (0615-0619)?
Weekly Report · 06/22 09:10
Weekly Report: what happened at IPHA last week (0608-0612)?
Weekly Report · 06/15 09:10
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 06/12 21:05
Weekly Report: what happened at IPHA last week (0601-0605)?
Weekly Report · 06/08 09:10
Weekly Report: what happened at IPHA last week (0525-0529)?
Weekly Report · 06/01 09:10
Weekly Report: what happened at IPHA last week (0518-0522)?
Weekly Report · 05/25 09:11
Innate Pharma management attends Jefferies Global Healthcare Conference 2026 one-on-one meetings
PUBT · 05/19 05:00
Innate Pharma to participate in the Jefferies Global Healthcare Conference
Barchart · 05/19 00:00
More
Webull provides a variety of real-time IPHA stock news. You can receive the latest news about Innate Pharma Sa through multiple platforms. This information may help you make smarter investment decisions.
About IPHA
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.